Abstract
In this study we retrorespectively reviewed dupilumab's efficacy and safety profile in treating elderly patients with atopic dermatitis (AD) and explored the predictive indicators for its efficacy. After analysing data from 181 patients we found that dupilumab appears to be effective and well-tolerated in treating AD among elderly patients. More importantly, we found that disease severity and early response to dupilumab are associated with complete remission at week 24 and may be used as potential predictive indicators for dupilumab's efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.